Metformin associated lactic acidosis: a case series of 28 patients treated with sustained low-efficiency dialysis (SLED) and long-term follow-up
暂无分享,去创建一个
M. Songini | A. Pani | M. Conti | M. Rosner | M. F. Mulas | G. Cabiddu | A. Angioi | Alice Atzeni | M. Floris | R. Cao | G. Pili | Valeria Matta
[1] E. Dimagno,et al. National Institute of Diabetes and Digestive and Kidney Diseases , 2020, Definitions.
[2] A. Sharif,et al. Metformin and other antidiabetic agents in renal failure patients. , 2015, Kidney international.
[3] R. Grant,et al. Trends in the Evidence Level for the American Diabetes Association's “Standards of Medical Care in Diabetes” From 2005 to 2014 , 2014, Diabetes Care.
[4] J. Halcox,et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controls , 2014, Diabetes, obesity & metabolism.
[5] Michael J. MacDonald,et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase , 2014, Nature.
[6] A. Protti,et al. Metformin accumulation: Lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy , 2014, Clinical toxicology.
[7] L. Pani,et al. Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. , 2013, European review for medical and pharmacological sciences.
[8] A. Khwaja. KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.
[9] M. Singer,et al. Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication , 2010, Critical care.
[10] G. Nichols,et al. Secondary Failure of Metformin Monotherapy in Clinical Practice , 2009, Diabetes Care.
[11] L. Marroquin,et al. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. , 2008, Toxicology and applied pharmacology.
[12] H. Howlett,et al. Metformin therapy and clinical uses , 2008, Diabetes & vascular disease research.
[13] Jianmin Tian,et al. Acute kidney injury criteria predict outcomes of critically ill patients* , 2008, Critical care medicine.
[14] Michael M. Engelgau,et al. Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.
[15] A. Morris,et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin , 2006, Diabetologia.
[16] U. Panzer,et al. Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] M. Andréjak,et al. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. , 2003, Diabetes & metabolism.
[18] H. Kusuhara,et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. , 2003, Molecular pharmacology.
[19] J. Lalau,et al. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin‐associated lactic acidosis’ , 2001, Diabetes, obesity & metabolism.
[20] Jonathan B. Brown,et al. Lactic Acidosis Rates in Type 2 Diabetes , 1998, Diabetes Care.
[21] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[22] A. Majid,et al. Bicarbonate haemodialysis as a treatment of metformin overdose. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] R. DeFronzo,et al. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.
[24] M. Mullee,et al. The Distribution and Severity of Diabetic Foot Disease: a Community Study with Comparison to a Non‐diabetic Group , 1992, Diabetic medicine : a journal of the British Diabetic Association.
[25] R. H. Williams,et al. Farewell to phenformin for treating diabetes mellitus. , 1975, Annals of internal medicine.
[26] C. G. Vermeij,et al. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements , 2011 .
[27] S. Nseir,et al. Metformin-associated lactic acidosis : A prognostic and therapeutic study * , 2009 .
[28] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.
[29] E. Salpeter,et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.
[30] J. Lalau,et al. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. , 1999, Drug safety.